Pharmaceutical Business Review

MARCH 7, 2024

Additionally, Sionna is progressing with the development of compounds targeting complementary mechanisms. This capital raise provides financial flexibility positioning us to execute our clinical development plan with funding through 2026 and multiple value-creating clinical readouts.”

Drug Development 59

Drug Development Compounding 59

European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 Advancements are underway in terms of product developments and innovations, with significant emphasis being placed on optimising and streamlining existing methods. percent CAGR between 2022 and 2026.

Dosage 111

Dosage Compounding Drug Development 111

pharmaphorum

MARCH 14, 2022

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Analgesic pre-clinical development. Drug development. Exploratory development. Sponsored by: CHDR. Million in 2018 and is projected to reach USD 15.87

Compounding 52

Compounding Drug Development 52

pharmaphorum

JUNE 2, 2022

Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ This is based on the relative success orphan drugs have achieved, in terms of the number of approvals and the sales figures achieved for this area.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Viseven

SEPTEMBER 18, 2024

When COVID hit, the urgent need to accelerate drug development meant shrinking timelines from years to months, with no room for compromises on quality. This innovative approach has brought more than 40 successful drug discovery projects to AstraZeneca. By the end of 2026, the company will be able to analyze two million genomes.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52